Tesamorelin
Fat LossGH Secretagogue / Fat Loss
GHRH analog for VAT research.
For research use only.
Key Facts
- CAS
- 804475-66-9
- Molecular Weight (MW)
- 5135.9 g/mol
- Half-life
- 26-38 minutes
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Daily
- Last updated
- 12/18/2025
- Targets
- Pituitary GHRH receptors
Overview
GHRH analog for VAT research.
Protocol
- Dosage Range
- 1-2 mg
- Frequency
- Daily
- Cycle
- 12-16 weeks on, 4 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 3 mL BAC for 10 mg vial
Science
Mechanism of Action
Stimulates pulsatile GH for VAT reduction.
Targets
Pituitary GHRH receptors
Studies
- — Journal/year not available
Benefits
Visceral fat lossMetabolic healthAnti-aging
Potential Side Effects
- Irritation
- Headache
- Flushing